Affymetrix Names GenoSplice as Its Preferred Data Analysis Service Provider
Increasing Accessibility for Bioinformatics in Genomic Research
SANTA CLARA, Calif. -- March 6, 2013
Affymetrix, Inc. (NASDAQ:AFFX) announced a co-marketing agreement today naming
GenoSplice, Inc. as its preferred data analysis service provider for the new
GeneChip^® Human Transcriptome Array 2.0, the most comprehensive microarray
available for alternative splicing detection. GenoSplice, a leader in genomic
data analysis and alternative splicing, has developed a dedicated expression
analysis solution, EASANA^®, including analysis for Affymetrix’ microarrays,
such as GeneChip^® Exon 1.0 ST Array, GeneChip^® Human Transcriptome Array
1.0, and the new GeneChip^® Human Transcriptome Array 2.0. When combined with
GenoSplice analysis services, these arrays provide the highest resolution
profiling of the transcriptome available on a microarray at both the gene and
“As part of Affymetrix’ commitment to provide end-to-end solutions, we are
enabling those without access to bioinformatics to utilize the most powerful
microarrays ever developed for the interrogation of alternative splicing
events. Now with so many options open to researchers, it is increasingly more
important to provide tools that generate biologically relevant results, not
just data,” commented Kevin Cannon, SVP – Expression Business Unit at
“We’re pleased to work with Affymetrix to combine two very powerful tools,
Affymetrix’ high resolution microarrays for gene expression profiling of
transcript isoforms and GenoSplice’s proprietary transcriptome data analysis
service, to help researchers save valuable time so they can focus on the
biology instead of on analytical details,” said Marc Rajaud, Co-CEO of
GenoSplice. “GeneChip^® Human Transcriptome Array 2.0 increases accessibility
to genomic research, resulting in new data that have to be interpreted to be
useful. Collaborating with Affymetrix helps keep GenoSplice on the forefront
of developing dedicated tools that streamline and simplify genomic data
PLEASE NOTE: Affymetrix^®, the Affymetrix logo, and GeneChip^® trademarks are
the property of Affymetrix, Inc. All other trademarks are the property of
their respective owners.
Products mentioned in this release are For Research Use only. Not for
SOURCE: Affymetrix, Inc.
GenoSplice develops and globally markets unique high level bioinformatics
analysis services for genomics data. The company provides in-house innovative
solutions for integrated genomics and is unique in offering user-friendly
support and long-term relationship for all next generation sequencing and
microarray platforms. Each client as each analysis is unique. GenoSplice
services mainly concern differential gene expression, alternative splicing,
miRNA, fusion transcript, epigenetics, SNP, CNV, translocation and proteomics
data. Visit www.genosplice.com for additional information.
Affymetrix technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and nonprofit research institutes. More than 2,300 microarray
systems have been shipped around the world and more than 48,000 peer-reviewed
papers have been published citing our technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing facilities in
Cleveland, Ohio, and Singapore. eBioscience is headquartered in San Diego,
California and has manufacturing facilities in San Diego and Vienna, Austria.
Including eBioscience, the Company has about 1,100 employees worldwide and
maintains sales and distribution operations across Europe, Asia, and Latin
America. For more information about Affymetrix, please visit
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2011, and other SEC reports for subsequent quarterly periods.
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
Doug Farrell, 408-731-5285
Vice President, Investor Relations
Marc Rajaud, +33 (0) 157-276-842
Press spacebar to pause and continue. Press esc to stop.